The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research.
Recent Opportunities
| Title | FOA | Post | Expire | Purpose | |
|---|---|---|---|---|---|
NIH |
NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional) | RFA-RM-20-012 | 2020-05-19 | 2020-08-22 | The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. |
NIH |
NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional) | RFA-RM-20-011 | 2020-05-19 | 2020-09-12 | The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. |
NIDDK |
NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional) | RFA-DK-20-002 | 2020-05-22 | 2020-10-21 | This Funding Opportunity Announcement (FOA) invites applications that propose a Center for Diabetes Translation Research (CDTR) to advance research along the spectrum of diabetes T2-T4 translational research (i.e., bedside to clinical practice and community settings, dissemination and implementation). The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. |
NIDDK |
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) | RFA-DK-20-021 | 2020-07-10 | 2020-12-17 | The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. |